medigraphic.com
ISSN 0210-5187 (Electronic)

2003, Number 2

<< Back Next >>

Med Cutan Iber Lat Am 2003; 31 (2)

Diagnosis and Treatment of Primary Cutaneous T-cell Lymphoma

Moreno-Ramírez D, Herrera SA, Camacho MF

Language: Spanish
References: 141
Page: 75-32
PDF size: 518.96 Kb.


ABSTRACT

Primary cutaneous lymphoma is an heterogeneous group of non-Hodgkin lymphomas showing a considerable variation in clinical presentation, histology, immunophenotype, and prognosis.
This variety, together with a different biological behaviour from their systemic counterparts led to the development of specific classifications, like the EORTC system.
Integration of clinical, histological, immunohistochemical, and genetic information is needed to reach the correct diagnosis of cutaneous lymphoma. Nevertheless, despite the application of molecular biology techniques a percentage of lymphomas are not correctly diagnosed.
Due to the favourable prognosis of early stages the lack of curative therapy regimens for cutaneous lymphoma, multiple strategies have been proposed for the management of this condition. This includes topical corticosteroids, nitrogen mustard and carmustine, phototherapy, radiotherapy, biological response modifiers (bexarotene and interferon), chemotherapy (gemcitabine, pentostatin, etc), among others. Clinical type and particularly the clinical stage, toxicity profile as well as response rates should be taken into account in order to select the suitable regimen for each patient. Current concepts about classification, therapies and guidelines for the management of T-cell cutaneous lymphoma are discussed in detail in this paper.


REFERENCES

  1. Willemze R, Kerl H, Sterry W et al. EORTC Classification for Primary Cutaneous Lymphomas: A proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer. Blood Review 1997;1:354-71.

  2. Gillian AC, Wood GS. Primary Cutaneous Lymphoma other than Mycosis Fungoides. Semin Oncol 1999;26:290-306.

  3. Weinstock MA, Horn JW. Mycosis Fungoides in the United States: Increasing incidence and descriptive epidemiology. JAMA 1988;260:42-6.

  4. Zackheim HS, Vonderheid EC, Ramsay DL et al. Relative frequency of various forms of primary cutaneous lymphomas. J Am Acad Dermatol 2000;43:793-6.

  5. Weinstock MA, Gardstein B. Twenty-year trends in the reported incidence of mycosis fungoides and associated mortality. Am J Public Health 1999;89:1240-4.

  6. Russell-Jones R. World Health Organization classification of hematopoietic and lymphoid tissues: implications for dermatology. J Am Acad Dermatol 2003;48:93-102.

  7. Estrach T. Clasificación de los linfomas cutáneos. Monogr Dermatol 2001;14:120-6.

  8. Willemze R, Meijer CJ. EORTC Classification for Primary Cutaneous Lymphomas: The best guide to good clinical management. Am J Dermatopathol 1999;21:265-73.

  9. Harris NL, Jaffe ES, Stein H et al. A Revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994;84:1361-92.

  10. Jaffe ES, Harris NL, Diebold J. World Health Organization Classification of Neoplastic Diseases of the Hematopoietic and Lymphoi Tissues. Am J Clin Pathol 1999;111:S8-S12.

  11. Bunn PA, Lamberg SI. Report of the Committee on Staging and Classification of Cutaneous T-Cell Lymphomas. Cancer Treat Rep 1979;63:725-8.

  12. Sausville EA, Eddy JL, Makuch RW et al. Histopathologic staging at initial diagnosis of mycosis fungoides and the Sezary syndrome. Definition of three distinctive prognostic groups. Ann Intern Med 1988;109:372-82.

  13. Martí RM, Estrach T. Linfomas Cutáneos. Med Cutan Iber Lat Am 1998;26:113-36.

  14. Estrach T. ¿Qué debe saber el dermatólogo “práctico” de la evaluación y tratamiento de los linfomas cutáneos?. Piel 2001;16:149-55.

  15. Fung MA, Murphy MJ, Hoss DM, Grant-Kels JM. Practical evaluation and management of cutaneous lymphoma. J Am Acad Dermatol 2002;46:325-57.

  16. Dalton JA, Yag-Howard C, Messina JL, Glass LF. Cutaneous T-cell lymphoma. Int J Dermatol 1997;36:801-9.

  17. Polo M, López I, Manteiga E, del Potro E. Linfomas cutáneos: definición, patogénesis, diagnóstico y clasificación. Rev Cancer (Madrid) 2000;14:1-37.

  18. Carbia SG, Hochman A, Dei-Cas I et al. Linfomas cutáneos ulcerados. Diez años de experiencia. Medicina (Buenos Aires) 2000;60:565-569.

  19. Howard MS, Smoller BR. Mycosis Fungoides: Classic disease and variant presentations. Semin Cutan Med Surg 2000;19:91-9.

  20. Spieth K, Grundmann-Kollmann M, Runne U et al. Mycosis-fungoides-type cutaneous T cell lymphoma of the hands and soles: a variant causing delay in diagnosis and adequate treatment of patients with palmoplantar eczema. Dermatology 2002;205:239-44.

  21. Bowman PH, Hogan DJ, Sanusi ID. Mycosis fungoides bullosa: report of a case and review of the literature. J Am Acad Dermatol 2001;45:934-9.

  22. Pujol RM, Gallardo F, Llistosella E et al. Invisible mycosis fungoides: A diagnostic challenge. J Am Acad Dermatol 2000;42:324-8.

  23. Izu R, Díaz-Ramón JL, Díaz-Pérez JL. Linfomas cutáneos de células T. Micosis fungoide. Síndrome de Sézary. Diagnóstico. Estudio de extension. Tratamiento. Monogr Dermatol 2001;14:149-62.

  24. Russell-Jones R, Whittaker S. T-cell receptor gene analysis in the diagnosis of Sezary syndrome. J Am Acad Dermatol 1999;41:254-9.

  25. Santucci M, Biggeri A, Feller AC et al. Efficacy of histologic criteria for diagnosing early mycosis fungoides. Am J Surg Pathol 2000;24:40-50. 26.Nickoloff BJ. Light-microscopic assessment of 100 patients with patch/plaque-stage mycosis fungoides. Am J Dermatopathol 1988;10:469-77.

  26. Nikoloff BJ. Light-microscopic assessment of 100 patients with patch/plaque-stage mycosis fungoides. Am J Dermatopathol 1988;10:469-77.

  27. Shapiro PE, Pinto FJ. The histologic spectrum of mycosis fungoides/Sezary syndrome (cutaneous T-cell lymphoma). A review of 222 biopsies, including newly described patterns and the earliest pathologic changes. Am J Surg Pathol 1994;18:645-67.

  28. Ackerman AB, Flaxman BA. Granulomatous mycosis fungoides. Br J Dermatol 1970;82:397-401.

  29. Van Doorn R, Sheffer E, Willemze R. Follicular mycosis fungoides, a distinct disease entity with or without associated follicular mucinosis. Arch Dermatol 2002;138:191-8.

  30. Van Haselen CW, Diederen PV, Toonstra J et al. The small-cell variant of mycosis fungoides. A clinicopathological and quantitative electron microscopic study on 14 patients. Arch Dermatol Res 1998;290:583-90.

  31. Trotter MJ, Whittaker SJ, Orchard GE, Smith NP. Cutaneous histopathology of Sezary syndrome: a study of 41 cases with a proven circulating T-cell clone. J Cutan Pathol 1997;24:286-91.

  32. Martí RM. Aplicaciones de la inmunohistoquímica al diagnóstico de los procesos linfoproliferativos cutáneos. Monogr Dermatol 2001;14:127-37.

  33. Cerroni L, Kerl H. The use of monoclonal antibodies on paraffin sections in the diagnosis of cutaneous lymphoproliferative disorders. Dermatol Clin 1994;12:219-29.

  34. Russell-Jones R, Whittaker S. Sezary syndrome: diagnostic criteria and therapeutic options. Semin Cutan Med Surg 2000;19:100-8.

  35. Santucci M, Pimpinelli N, Massi D et al. Cytotoxic/natural killer cell cutaneous lymphomas. Report of EORTC Cutaneous Lymphoma Task Force Workshop. Cancer. 2003 Feb 1;97(3):610-27.

  36. Ortiz P. Aplicación de las técnicas de biología molecular para el diagnóstico de los linfomas cutáneos. Monogr Dermatol 2001;14:138-48.

  37. Holm N, Flaig MJ, Yazdi AS, Sander CA. The value of molecular analysis by PCR in the diagnosis of cutaneous lymphocytic infiltrates. J Cutan Pathol 2002;29:447-52.

  38. Flaig MJ, Schuhmann K, Sander CA. Impact of molecular analysis in the diagnosis of cutaneous lymphoid infiltrates. Semin Cutan Med Surg 2000;19:87-90.

  39. Bachelez H, Bioul L, Flageul B et al. Detection of clonal T-cell receptor gamma gene rearrangements with the use of the polymerase chain reaction in cutaneous lesions of mycosis fungoides and Sezary syndrome. Arch Dermatol 1995;131:1027-31.

  40. Wood GS, Tung RN, Haeffner AC y cos. Detection of clonal T-cell receptor gamma gene rearrangemets in early mycosis fungoides/Sézary syndrome by PCR and DG-GE. J Invest Dermatol 1994;103:34-41.

  41. Cerroni L. The value of gene rearrangement studies and other molecular analyses for early diagnosis of cutaneous lymphoma. EORTC Cutaneous Lymphoma Task Force Clinical Meeting; 13-15 Junio 2003; Helsinki.

  42. Delfau-Larue MH, Petrella T, Lahet C et al. Value of clonality studies of cutaneous T lymphocytes in the diagnosis and follow-up of patients with mycosis fungoides. J Pathol 1998;184:185-90.

  43. Delfau-Larue MH, Dalac S, Lepage E et al. Prognostic significance of a polymerase chain reaction-detectable dominant T-lymphocyte clone in cutaneous lesions of patients with mycosis fungoides. Blood. 1998 1;92:3376-80.

  44. Kern DE, Kidd PG, Moe R, Hanke D, Olerud JE. Analysis of T-cell receptor gene rearrangement in lymph nodes of patients with mycosis fungoides. Prognostic implications. Arch Dermatol 1998;134:158-64.

  45. Bakels V, Van Oostveen JW, Geerts ML et al. Diagnostic and prognostic significance of clonal T-cell receptor beta gene rearrangements in lymph nodes of patients with mycosis fungoides. J Pathol 1993;170:249-55.

  46. Fraser-Andrews EA, Woolford AJ, Russell-Jones R et al. Detection of a peripheral blood T cell clone is an independent prognostic marker in mycosis fungoides. J Invest Dermatol 2000;114:117-21.

  47. Muche JM, Lukowsky A, Asadullah K et al. Demonstration of frequent occurrence of clonal T cells in the peripheral blood of patients with primary cutaneous T-cell lymphoma. Blood 1997;90:1636-42.

  48. Fraser-Andrews EA, Russell-Jones R, Woolford AJ et al. Diagnostic and prognostic importance of T-cell receptor gene analysis in patients with Sezary syndrome. Cancer 2001;92:1745-52.

  49. Scarisbrick JJ, Whittaker S, Evans AV et al. Prognostic significance of tumor burden in the blood of patients with erythrodermic primary cutaneous T-cell lymphoma. Blood 2001;97:624-30.

  50. Guitart J, Kaul K. A new polymerase chain reaction-based method for the detection of T-cell clonality in patients with possible cutaneous T-cell lymphoma. Arch Dermatol 1999;135:158-62.

  51. Bignon YJ, Souteyrand P. Genotyping of cutaneous T-cell lymphomas and pseudolymphomas. Curr Probl Dermatol 1990;19:114-23.

  52. Kulin PA, Marglin SI, Shuman WP et al. Diagnostic imaging in the initial staging of mycosis fungoides and Sezary syndrome. Arch Dermatol 1990;126:914-8.

  53. Howlett DC, Wong WL, Smith NP, Ayers AB. Computed tomography in the evaluation of cutaneous T-cell lymphoma. Eur J Radiol 1995;20:39-42.

  54. Bass JC, Korobkin MT, Cooper KD et al. Cutaneous T-cell lymphoma: CT in evaluation and staging. Radiology. 1993;186:273-8.

  55. Miketic LM, Chambers TP, Lembersky BC. Cutaneous T-cell lymphoma: value of CT in staging and determining prognosis. AJR Am J Roentgenol 1993;160:1129-32.

  56. Shapiro M, Yun M, Junkins-Hopkins JM et al. Assessment of tumor burden and treatment response by 18F-fluorodeoxyglucose injection and positron emission tomography in patients with cutaneous T- and B-cell lymphomas. J Am Acad Dermatol 2002;47:623-8.

  57. Breneman DL, Raju US, Breneman JC et al. Lymph node grading for staging of mycosis fungoides may benefit from examination of multiple excised lymph nodes. J Am Acad Dermatol 2003;48:702-6.

  58. Martí RM, Estrach T, Reverter JC et al. Utility of bone marrow and liver biopsies for staging cutaneous T-cell lymphoma. Int J Dermatol 1996;35:450-4.

  59. Zackheim HS, Amin S, Kashani-Sabet M, McMillan A. Prognosis in cutaneous T-cell lymphoma by skin stage: Long-term survival in 489 patients. J Am Acad Dermatol 1999;40:418-25.

  60. Grange F, Bagot M. Pronostic des lymphomes cutanés primitifs. Ann Dermatol Venereol 2002;129:30-40.

  61. Van Doorn R, Van Haselen CW, van Voorst Vader PC et al. Mycosis fungoides: disease evolution and prognosis of 309 Dutch patients. Arch Dermatol 2000;136:504-10.

  62. Kim YH, Bishop K, Varhese, Hoppe RT. Prognostic factors in erythrodermic mycosis fungoides and the Sézary syndrome. Arch Dermatol 1995;131:1003-8.

  63. Diamandidou E, Colome M, Fayad L. Prognostic factor analysis in mycosis fungoides/Sézary syndrome. J Am Acad Dermatol 1999;40:914-24.

  64. Martí RM, Estrach T, Reverter JC, Mascaró JM. Prognostic clinicopathologic factors in cutaneous T-cell lymphoma. Arch Dermatol 1991;127:1511-16.

  65. Meissner K, Michaelis K, Rehpenning W, Loning T. Epidermal Langerhans’ cell densities influence survival in mycosis fungoides and Sezary syndrome. Cancer 1990;65:2069-73.

  66. Hoppe RT, Medeiros LJ, Warnke RA, Wood GS. CD8-positive tumor-infiltrating lymphocytes influence the long-term survival of patients with mycosis fungoides. J Am Acad Dermatol 1995;32:448-53.

  67. Toro JR, Stoll HL, Stomper PC, Oseroff AR. Prognostic factors and evaluation of mycosis fungoides and Sézary syndrome. J Am Acad Dermatol 1997;37:58-67.

  68. Wasik MA, Vonderheid EC, Bigler RD et al. Increased serum concentration of the soluble interleukin-2 receptor in cutaneous T-cell lymphoma. Clinical and prognostic implications. Arch Dermatol 1996;132:42-7.

  69. Manteiga E, del Potro E, Polo M, López I. Avances en la terapéutica de los linfoma cutáneos. Rev Cancer (Madrid) 2000;14:28-37.

  70. Duvic M. Current treatment of Cutaneous T-Cell Lymphoma. Dermatol Online J 2001;7:3.

  71. Muche JM, Gellrich S, Sterry W. Treatment of Cutaneous T-Cell Lymphomas. Semin Cutan Med Surg 2000;2:142-148.

  72. Apisarnthanarax N, Talpur R, Duvic M. Treatment of cutaneous T cell lymphoma. Am J Clin Dermatol 2002;3:193-215.

  73. Zackheim HS, Kashani-Sabet, Smita A. Topical steroids for mycosis fungoides. Experience in 79 patients. Arch Dermatol 1998;134:949-54.

  74. Drews R, Samel A, Kadin ME. Lymphomatoid papulosis and anaplastic large cell lymphomas of the skin. Semin Cutan Med Surg 2000;19:109-17.

  75. Krathen RA, Ward S, Duvic M. Bexarotene is a new treatment option for lymphomatoid papulosis. Dermatology 2003;206:142-7.

  76. Ramsay DL, Meller JA, Zackheim HS. Topical treatment of early cutaneous T-cell lymphoma. Hematol Oncol Clin North Am 1995;9:1031-55.

  77. Kim YH, Martinez G, Varghese A, Hoppe RT. Topical nitrogen mustard in the management of mycosis fungoides: update of the Stanford experience. Arch Dermatol 2003;139:165-73.

  78. Zackheim HS.Topical and intralesional chemotherapeutic agents. En: Wolverton SE ed. Comprehensive Dermatologic Drug Therapy. Philadelphia: WB Saunders Company, 2001; p. 595-606.

  79. Zackheim HS, Epstein EH, Crain WR. Topical carmustine (BCNU) for cutaneous T cell lymphoma: a 15-year experience in 143 patients. J Am Acad Dermatol 1990;22:802-10.

  80. Zackheim HS. Topical carmustine (BCNU) for patch/plaque mycosis fungoides. Semin Dermatol 1994;13:202-6.

  81. Breneman D, Duvic M, Martin A et al. Long-term treatment of patients with early stage cutaneous T-cell lymphoma with bexarotene gel 1%. Póster 229. 60th Annual Meeting of the American Academy of Dermatology; 22-27 Febrero 2002; New Orleans (LA).

  82. Suchin KR, Junkins-Hopkins JM, Rook AH. Treatment of stage IA cutaneous T-Cell lymphoma with topical application of the immune response modifier imiquimod. Arch Dermatol 2002;138:1137-9.

  83. Muche JM, Born A, Sterry W, Gellrich S. Imiquimode in the treatment of cutaneous T cell lymphoma. EORTC Cutaneous Lymphoma Task Force Clinical Meeting; 13-15 Junio 2003; Helsinki.

  84. Ramsay DL, Lish KM, Yalowitz CB, Soter NA. Ultraviolet-B phototherapy for early-stage cutaneous T-cell lymphoma. Arch Dermatol 1992;128:931-3.

  85. Resnik KS, Vonderheid EC. Home UV phototherapy of early mycosis fungoides: long-term follow-up observations in thirty-one patients. J Am Acad Dermatol 1993;29:73-7.

  86. Zanolli MD. Cutaneous T-cell lymphoma. En: Zanolli MD, Feldman SR, Clark A, Fleischer A eds. Phototherapy treatment protocols for psoriasis and other phototherapy responsive dermatoses. New York: Parthenon Publishing, 2000;p.107-17.

  87. Clark C, Dawe RS, Evans AT et al. Narrowband TL-01 phototherapy for patch-stage mycosis fungoides. Arch Dermatol. 2000;136:748-52.

  88. Hofer A, Cerroni L, Kerl H, Wolf P. Narrowband (311-nm) UV-B therapy for small plaque parapsoriasis and early-stage mycosis fungoides. Arch Dermatol 1999;135:1377-80.

  89. Herrmann JJ, Roenigk HH, Honigsmann H. Ultraviolet radiation for treatment of cutaneous T-cell lymphoma. Hematol Oncol Clin North Am 1995;9:1077-88.

  90. Herrmann JJ, Roenigk HH, Hurria A et al. Treatment of mycosis fungoides with photochemotherapy (PUVA): long-term follow-up. J Am Acad Dermatol 1995;33:234-42.

  91. Edelson R, Berger C, Gasparro F et al. Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. N Engl J Med 1987;316:297-303.

  92. Heald P, Pérez M, Christensen I et al. Photopheresis therapy of cutaneous T-cell lymphoma: The Yale-New Haven hospital experience. Yale Biol Med 1989;62:629-38.

  93. Duvic M, Hester J, Lemak A. Photopheresis therapy for cutaneous T-cell lymphoma. J Am Acad Dermatol 1996;35:573-9.

  94. Russell-Jones R, Fraser-Andrews E, Spittle M et al. Extracorporeal photopheresis in Sézary syndrome. Lancet 1997;350:886.

  95. Rook AH, Suchin KR, Kao DM et al. Photopheresis: clinical applications and mechanism of action. J Investig Dermatol Symp Proc 1999;4:85-90.

  96. Russell-Jones R. Extracorporeal photo-pheresis in cutaneous T-cell lymphoma: inconsistent data underlie the need for randomized structures. Br J Dermatol 2000;142:16-21.

  97. Jones GW, Kacinski BM, Wilson LD et al. Total skin electron radiation in the management of mycosis fungoides: Consensus of the European Organization for Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Project Group. J Am Acad Dermatol 2002;47:364-70.

  98. Olsen E, Bunn PA. Interferon in the treatment of cutaneous T-cell lymphoma. Hematol Oncol Clin North Am 1995;9:1089-107.

  99. Jumbou O, N’Guyen JM, Tessier MH et al. Long-term follow-up in 51 patients with mycosis fungoides and Sézary syndrome treated by interferon-alfa. Br J Dermatol 1999;140:427-31.

  100. Ross C, Tingsgaard P, Jorgensen H et al. Interferon treatment of cutaneous T-cell lymphoma. Eur J Haematol 1993;51:63-72.

  101. Wolff JM, Zitelli JA, Rabin BS et al. Intralesional interferon in the treatment of early mycosis fungoides. J Am Acad Dermatol 1985;13:604-12.

  102. Quesada JR, Talpaz M, Ríos A et al. Clinical toxicity of interferons in cancer patients: A review. J Clin Oncol 1986;4:234-43.

  103. Koh LK, Greenspan FS, Yeo PP. Interferon-alpha induced thyroid dysfunction: three clinical presentations and a review of the literature. Thyroid 1997;7:891-6.

  104. Wong SF. Oral bexarotene in the treatment of cutaneous T-cell lymphoma. Ann Pharmacother 2001;35:1056-65.

  105. Duvic M, Hymes K Heald P and cols. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell Lymphoma: multinational phase II-III trial results. J Clin Oncol 2001;19:581-93.

  106. Duvic M, Martin AG, Kim Y et al. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Arch Dermatol 2001;137:581-93.

  107. Vittorio CC, Rook AH, French LE et al. Therapeutic advances in biological response modifiers in the treatment of cutaneous T-cell lymphoma. BioDrugs 2001;15:431-7.

  108. Talpur R, Ward S, Apisarnthanarax N et al. Optimizing bexarotene therapy for cutaneous T-cell lymphoma. J Am Acad Dermatol 2002;47:672-84.

  109. Marolleau JP, Baccard M, Flageul B y colaboradoresHigh-dose recombinant interleukin-2 in advanced cutaneous T-cell lymphoma. Arch Dermatol 1995;131:574-9.

  110. Rook AH, Zaki MH, Wysocka M et al. The role for interleukin-12 therapy of cutaneous T cell lymphoma. Ann N Y Acad Sci 2001;941:177-84.

  111. Duvic M, Rook A, Foss F et al. A phase 2 open-label study of recombinant human interleukin-12 (Ril-12) in patients with stage Ia, Ib or IIa cutaneous T-cell lymphoma (CTCL). Póster 82. 36th Annual Meeting of the American Society of Clinical Oncology; 20-23 Mayo 2000; New Orleans (LA).

  112. Foss FM. DAB389IL-2 (ONTAK): A novel fusion toxin therapy for lymphoma. Clin Lymphoma 2000;1:110-6.

  113. Olsen E, Duvic M, Frankel A et al. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol 2001;19:376-88.

  114. Duvic M, Cather J, Maize J, Frankel AE. DAB389IL2 diphtheria fusion toxin produces clinical responses in tumor stage cutaneous T cell lymphoma. Am J Hematol 1998;58:87-90.

  115. Foss FM, Bacha P, Kuzel TM. Biological correlates of acute hypersensitivity events with DAB389IL-2 (denileukin diftitox) in cutaneous T-cell lymphoma: decreased frequency and severity with steroid premedication. Clin Lymphoma 2001;1:298-302.

  116. Flynn JM, Byrd JC. Campath-1H monoclonal antibody therapy. Curr Opin Oncol 2000;12:574-81.

  117. Lundin J, Osterborg A, Brittinger G et al. CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin’s lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin’s Lymphoma. J Clin Oncol 1998;16:3257-63.

  118. Dearden CE. CAMPATH-1H in cutaneous T-cell lymphoma. EORTC Cutaneous Lymphoma Task Force Clinical Meeting; 13-15 Junio 2003; Helsinki.

  119. Case DC. Combination chemotherapy for mycosis fungoides with cyclophosphamide, vincristine, methotrexate, and prednisone. Am J Clin Oncol 1984;7:453-5.

  120. Fierro MT, Quaglino P, Savoia P et al. Systemic polychemotherapy in the treatment of primary cutaneous lymphomas: a clinical follow-up study of 81 patients treated with COP or CHOP. Leuk Lymphoma 1998;31:583-8.

  121. Rosen ST, Foss FM. Chemotherapy for mycosis fungoides and the Sezary syndrome. Hematol Oncol Clin North Am 1995;9:1109-16.

  122. Zackheim HS, Kashani-Sabet M, Hwang ST. Low-dose methotrexate to treat erythrodermic cutaneous T-cell lymphoma: Results in twenty-nine patients. J Am Acad Dermatol 1996;34:626-31.

  123. Vonderheid EC, Sajjadian A, Kadin ME. J Methotrexate is effective therapy for lymphomatoid papulosis and other primary cutaneous CD30-positive lymphoproliferative disorders. J Am Acad Dermatol 1996;34:470-81.

  124. Abd-el-Baki J, Demierre MF, Li N, Foss FM. Transformation in mycosis fungoides: the role of methotrexate. J Cutan Med Surg 2002;6:109-16.

  125. Zinzani PL, Baliva G, Magagnoli M et al. Gemcitabine treatment in pretreated cutaneous T-cell lymphoma: experience in 44 patients. J Clin Oncol 2000;18:2603-6.

  126. Von Hoff DD, Dahlberg S, Hartstock RJ, Eyre HJ. Activity of fludarabine monophosphate in patients with advanced mycosis fungoides: a Southwest Oncology Group study. J Natl Cancer Inst 1990;82:1353-5.

  127. Scarisbrick JJ, Child FJ, Clift A et al. A trial of fludarabine and cyclophosphamide combination chemotherapy in the treatment of advanced refractory primary cutaneous T-cell lymphoma. Br J Dermatol 2001;144:1010-5.

  128. Foss FM, Ihde DC, Linnoila IR et al. Phase II trial of fludarabine phosphate and interferon alfa-2a in advanced mycosis fungoides/Sezary syndrome. J Clin Oncol 1994;12:2051-9.

  129. Foss FM. Activity of pentostatin (Nipent) in cutaneous T-cell lymphoma: single-agent and combination studies. Semin Oncol 2000;27:58-63.

  130. Dearden C, Matutes E, Catovsky D. Pentostatin treatment of cutaneous T-cell lymphoma. Oncology (Huntingt) 2000;14:37-40.

  131. Greiner D, Olsen EA, Petroni G. Pentostatin (2’ –deoxycoformycin) in the treatment of cutaneous T-cell lymphoma. J Am Acad Dermatol 1997;36:950-5.

  132. Kuzel TM, Hurria A, Samuelson E et al. Phase II trial of 2-chlorodeoxyadenosine for the treatment of cutaneous T-cell lymphoma. Blood. 1996 Feb 1;87(3):906-11.

  133. Harland CC, Balsitis M, Millard LG. Sezary-type cutaneous T-cell leukaemia. Response to Winkelmann regimen. Acta Derm Venereol 1990;70:251-3.

  134. Winkelmann RK, Diaz-Perez JL, Buechner SA. The treatment of Sezary syndrome. J Am Acad Dermatol 1984;10:1000-4.

  135. Wieselthier JS, Koh HK. Sezary syndrome: diagnosis, prognosis, and critical review of treatment options. J Am Acad Dermatol 1990;22:381-401.

  136. Masood N, Russell KJ, Olerud JE et al. Induction of complete remission of advanced stage mycosis fungoides by allogeneic hematopoietic stem cell transplantation. J Am Acad Dermatol 2002;47:140-5.

  137. Burt RK, Guitart J, Traynor A et al. Allogeneic hematopoietic stem cell transplantation for advanced mycosis fungoides: evidence of a graft-versus-tumor effect. Bone Marrow Transplant 2000;25:111-3.

  138. Chinn DM, Chow S, Kim YH, Hoppe RT. Total skin electron beam therapy with or without adjuvant topical nitrogen mustard or nitrogen mustard alone as initial treatment of T2 and T3 mycosis fungoides. Int J Radiat Oncol Biol Phys 1999;43:951-8.

  139. McGinnis KS, Shapiro M, Vittorio CC et al. Psoralen plus long-wave UV-A (PUVA) and bexarotene therapy: An effective and synergistic combined adjunct to therapy for patients with advanced cutaneous T-cell lymphoma. Arch Dermatol 2003;139:771-5.

  140. French LE, Shapiro M, Junkins-Hopkins JM et al. Regression of multifocal, skin-restricted, CD30-positive large T-cell lymphoma with interferon alfa and bexarotene therapy. J Am Acad Dermatol 2001;45:914-8.

  141. Duvic M. Bexarotene and DAB(389)IL-2 (denileukin diftitox, ONTAK) in treatment of cutaneous T-cell lymphomas: algorithms. Clin Lymph 2000;1:S51-5.




2020     |     www.medigraphic.com